01—Abstract
Summary
Summary of the 10-Q filed June 3, 2024. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported a decrease in net revenue for the third quarter and first six months of fiscal year 2024, down 8%a and 7% respectively, compared to the prior year.
This decline was primarily driven by the Life Sciences and Applied Markets segment and the Diagnostics and Genomics segment, impacted by customer capital expenditure pressures, particularly in the pharmaceutical market. The Agilent CrossLab segment showed resilience with revenue growth in both periods. Despite the revenue decline, net income remained stable, with $308 millionb reported for the third quarter and $656 million for the first six months, slightly up from the prior year.
Operating cash flow significantly improved, reaching $818 millionc for the first six months of fiscal year 2024, up from $694 million in the comparable prior-year period. The company also announced a new restructuring plan (FY24 Plan) aimed at further cost reductions, involving approximately 500 employee reductions, with an estimated annual cost savings of $100 million. Additionally, a new $2.0 billion share repurchase program was approved, effective August 1, 2024.
02—Key points
Key Highlights
- Net revenue decreased by 8% year-over-year for the third quarter and 7% for the first six months of fiscal year 2024.
- Life Sciences and Applied Markets and Diagnostics and Genomics segments experienced revenue declines, while Agilent CrossLab saw growth.
- Net income remained stable year-over-year, with $308 million for Q3 FY24 and $656 million for the first six months of FY24.
- Operating cash flow increased significantly to $818 million for the first six months of FY24, up from $694 million in the prior year.
- The company announced a new restructuring plan (FY24 Plan) targeting approximately 500 employee reductions for further cost savings.
- A new $2.0 billion share repurchase program was authorized, effective August 1, 2024.
- The company continues to face capital expenditure pressures from customers, particularly in the pharmaceutical market.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Agilent Technologies, Inc. kept $0.20.
- Revenue$1.57B100.0%
- Cost of revenue−$717.0M45.6%
- Gross profit$856.0M54.4%
- Operating costs−$493.0M31.3%
- Operating income$363.0M23.1%
- Interest, other & tax−$55.0M3.5%
- Net income$308.0M19.6%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed June 3, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $1.57B$1.72B | −8.4% |
| Cost of Revenue | $717.00M$793.00M | −9.6% |
| Gross Profit | $856.00M$924.00M | −7.4% |
| R&D Expenses | $113.00M$126.00M | −10.3% |
| SG&A Expenses | $380.00M$415.00M | −8.4% |
| Operating Expenses | $1.21B$1.33B | −9.3% |
| Operating Income | $363.00M$383.00M | −5.2% |
| Interest Expense | $20.00M$24.00M | −16.7% |
| Net Income | $308.00M$302.00M | +2.0% |
| EPS (Basic) | $1.05$1.02 | +2.9% |
| EPS (Diluted) | $1.05$1.02 | +2.9% |
| Shares Outstanding (Basic) | 293.00M296.00M | −1.0% |
| Shares Outstanding (Diluted) | 293.00M297.00M | −1.3% |
05—Questions
Frequently Asked Questions
What drove the decline in Agilent's revenue for the quarter?
Agilent's revenue declined primarily due to decreases in its Life Sciences and Applied Markets and Diagnostics and Genomics segments. This was largely influenced by customers' continued capital expenditure pressures, particularly within the pharmaceutical market, and a significant decline in revenue in China.
How did the company's profitability hold up despite the revenue decrease?
Despite the revenue decline, Agilent's net income remained stable year-over-year, indicating effective cost management and a favorable business mix. The Agilent CrossLab segment's growth also helped offset declines in other segments. Furthermore, operating cash flow saw a significant improvement.
What is the company doing to address current macroeconomic challenges and improve cost structure?
Agilent announced a new restructuring plan (FY24 Plan) involving a reduction of approximately 500 employees, which is expected to yield approximately $100 million in annual cost savings. They also continue to implement targeted pricing and other cost-saving strategies to mitigate inflationary pressures.
What is the outlook for Agilent's different business segments?
The Life Sciences and Applied Markets and Diagnostics and Genomics segments are expected to continue facing revenue challenges due to customer capital expenditure pressures and market conditions. However, the Agilent CrossLab segment is well-positioned for continued success and growth due to the demand for its services and its diversified geographic presence.
06—Continue